Publications by authors named "Elena Elli"

Claim this Profile
H
Health-related quality of life and symptom profile of patients with -negative myeloproliferative neoplasms: Real-world evidence from the GIMEMA-PROPHECY observational study.
Giovanni Caocci, Alessandro Costa, Francesca Palandri, Paola Guglielmelli, Andrea Patriarca, Elena Maria Elli

Hemasphere· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The 2024 Three-Strata Baseline Anemia Definition of the Revised IWG-ELN Criteria Dissects Survival in Ruxolitinib-Treated Myelofibrosis Patients.
Margherita Maffioli, Barbara Mora, Alessandra Iurlo, Elena Maria Elli, Maria Chiara Finazzi

Am J Hematol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib.
Francesca Palandri, Filippo Branzanti, Massimiliano Bonifacio, Elena M Elli, Erika Morsia, Mario Tiribelli

Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with front-line hydroxyurea.
Francesca Palandri, Massimo Breccia, Elena M Elli, Roberto Latagliata, Giulia Benevolo, Mario Tiribelli

Leukemia· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis.
Francesca Palandri, Massimo Breccia, Erika Morsia, Elena M Elli, Giulia Benevolo, Mario Tiribelli

Clin Lymphoma Myeloma Leuk· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment strategies and survival after ruxolitinib discontinuation in myelofibrosis patients: The Italian RUX-MF multicenter study.
Francesca Palandri, Massimo Breccia, Erika Morsia, Elena M Elli, Giulia Benevolo, Mario Tiribelli

Leuk Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study design.
Valerio De Stefano, Francesco Passamonti, Francesca Palandri, Francesco Ramundo, Elena Rossi, Paola Guglielmelli, Elena Maria Elli, Elena Masselli

Ann Hematol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real-world setting: Interim results of the Italian observational study (ROMEI).
Massimo Breccia, Francesca Palandri, Maurizio Martelli, Francesco Mendicino, Alessandra Malato, Elena Maria Elli, Angelo Gardellini, Mario Tiribelli, Paola Guglielmelli

Cancer· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neutrophil-to-lymphocyte ratio (NLR) at diagnosis in essential thrombocythemia: A new promising predictor of thrombotic events.
Alessia Ripamonti, Fabrizio Cavalca, Laura Montelisciani, Laura Antolini, Carlo Gambacorti-Passerini, Elena Maria Elli

Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy.
Francesca Palandri, Filippo Branzanti, Erika Morsia, Alessandra Dedola, Giulia Benevolo, Mario Tiribelli, Elena M Elli

Ann Hematol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study.
Francesca Palandri, Elena M Elli, Erika Morsia, Giulia Benevolo, Mario Tiribelli, Nicola Vianelli

Cancer· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: The ARES trial.
Bianca Rocca, Alberto Tosetto, Giovanna Petrucci, Elena Rossi, Silvia Betti, Cristina Bucelli, Nicola Vianelli, Elena Maria Elli

Am J Hematol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy.
Francesca Palandri, Giuseppe A Palumbo, Giulia Benevolo, Alessandra Iurlo, Elena M Elli, Nicola Polverelli, Mario Tiribelli, Nicola Vianelli

Cancer· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis.
Ilaria Crespiatico, Mattia Zaghi, Cristina Mastini, Deborah D'Aliberti, Mario Mauri, Silvia Spinelli, Federica Mottadelli, Elena Maria Elli

Blood· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigation of Serum Albumin as a Dynamic Treatment-Specific Surrogate for Outcomes in Patients With Myelofibrosis Treated With Ruxolitinib.
Andrew T Kuykendall, Somedeb Ball, Barbara Mora, Qianxing Mo, Najla Al Ali, Elena M Elli

JCO Precis Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis.
Francesca Palandri, Giuseppe A Palumbo, Massimiliano Bonifacio, Elena M Elli, Mario Tiribelli, Nicola Polverelli, Nicola Vianelli

Cancers (Basel)· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of blast phase in myelofibrosis according to anemia severity.
Barbara Mora, Margherita Maffioli, Elisa Rumi, Paola Guglielmelli, Marianna Caramella, Elena M Elli, Nicola Polverelli

EJHaem· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study.
Francesca Palandri, Elena Rossi, Giuseppe Auteri, Massimo Breccia, Simona Paglia, Elena M Elli, Mario Tiribelli, Nicola Polverelli, Nicola Vianelli

Cancers (Basel)· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome.
Francesca Palandri, Massimo Breccia, Camilla Mazzoni, Giuseppe Auteri, Elena Maria Elli, Nicola Polverelli, Mario Tiribelli, Nicola Vianelli

Cancer· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Differential Diagnosis in the WHO and ICC 2022 Era: A Focused Review.
Diletta Fontana, Elena M Elli, Fabio Pagni, Rocco Piazza

Cancers (Basel)· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib.
Francesca Palandri, Elena M Elli, Giuseppe Auteri, Massimiliano Bonifacio, Giulia Benevolo, Mario Tiribelli, Nicola Polverelli, Caterina Tatarelli, Nicola Vianelli

Blood Cancer J· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia.
Elena Inzoli, Elena Crisà, Novella Pugliese, Ivan Civettini, Giuseppe Lanzarone, Andrea Castelli, Vincenzo Martinelli, Elena Maria Elli

Eur J Haematol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project.
Giacomo Coltro, Emanuela Sant'Antonio, Giuseppe A Palumbo, Francesco Mannelli, Valerio De Stefano, Elena M Elli, Paola Guglielmelli

Cancer Med· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of polycythemia vera: A survey of treatment patterns in Italy.
Giuseppe Alberto Palumbo, Massimo Breccia, Claudia Baratè, Massimiliano Bonifacio, Elena Maria Elli, Paola Guglielmelli

Eur J Haematol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breakthrough infections in MPN-COVID vaccinated patients.
Tiziano Barbui, Alessandra Carobbio, Arianna Ghirardi, Alessandra Iurlo, Valerio De Stefano, Elena Maria Elli, Paola Guglielmelli, Marta Bellini, Cristina Bucelli

Blood Cancer J· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis